San Francisco Bay Area - Ingelheim am Rhein | | Investor Type | Corporate VC |
| Type of Fund | Corporate VC |
| Industries | BioTech • HealthTech (& Fitness) • Cannabis • Medical Devices (& Hospital Services) • Healthcare (& Wellness) • Investment Management • Life Science • Consumer • Pharmaceutical (& Medicine) • Diagnostics |
| Stages | Seed, Startup, Early Stage, Series A, Series B, Pre-seed |
| Investing | United States • United Kingdom • Canada • Germany • France • Spain • Sweden • China • Switzerland • Denmark • Singapore • Hong Kong • Portugal • Israel • Belgium • Austria • Europe |
| Investment Range | $3,300,000 - $17,000,000 |
| Investment Sweet Spot | $8,500,000 |
| Assets Under Management | $100,000,000 |
What is Boehringer Ingelheim Venture Fund?
Boehringer Ingelheim Venture Fund (BIVF) is the strategic corporate venture capital arm of Boehringer Ingelheim, focused on advancing biopharmaceutical innovation. BIVF was established in 2010, with a mandate to invest in groundbreaking therapeutic approaches and technologies that have the potential to advance patient care and deliver significant health benefits. The fund is headquartered in Ingelheim am Rhein, Rheinland-Pfalz, Germany, reflecting its roots in one of the world's leading pharmaceutical companies.
With an assets under management of around 100 million euros, BIVF deploys its investments across a broad range of life sciences sectors including but not limited to BioTech, HealthTech, Medical Devices, Healthcare, Life Science, and Pharmaceuticals. The fund is actively involved in Seed, Startup, Early Stage, Series A, and Series B financing rounds. BIVF’s equity investments range typically from 3.3 to 17 million euros, with a sweet spot around 8.5 million euros.
As a global investor, BIVF has a non-restrictive geographic approach to investment, seeking opportunities worldwide to ensure it captures the best innovative solutions irrespective of location.
The investment fund's portfolio includes investments in Digital Health, Oncology, Regenerative Medicine, and other related technologies. BIVF is known for its strategic contributions to the companies it invests in, leveraging Boehringer Ingelheim's extensive research and development expertise.
The fund aims to create value by providing patient-centered healthcare solutions, while also delivering on the promise of science and innovative treatment options.
What they say:
We are a venture fund seeking groundbreaking approaches and innovative technologies.
What we look for: We invest in biotech and therapeutics ventures.
Boehringer Ingelheim Venture Fund's investments on record
What are the investment firms similar to Boehringer Ingelheim Venture Fund
Eden Ventures
Allistro Capital
Econnoa
SEB Asset Management
Main Incubator
Finance in Motion
KfW Group
VCDE Venture Partners
Rantum Capital
DTC Ventures
Contact over 100,000 investors!
Built by serial entrepreneurs and ex-VCs, Angels Partners helps entrepreneurs connect with relevant investors in their industry.
With over 100K+ listed investors, our mission is to help founders secure meetings & accelerate their fundraising.
View previous deals, filter by deal size, industry, location and more. It's the fastest way to build a target investor list.
We also built a community of hundreds of investors actively prospecting & investing directly on Angels Partners.
Register to become visible to a large community of investors on our platform.
- Prime Founders
- 71-75 Shelton Street, Covent Garden, WC2H 9JQ
- London, U.K.
- contact@angelspartners.com
